Medical device firm NeuroMetrix is planning to unveil its new wearable pain relief device, Quell, in January 2015.
It will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas, US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Quell is designed for consumers looking for non-pharmacological pain control options.
Featuring the company’s non-invasive neurostimulation technology, the device will provide relief from chronic pain, specifically neuropathic pain that result due to diabetes and lower back problems.
The company said this advanced lightweight wearable device can be worn during the day while active and at night while sleeping.
The device was cleared by US Food and Drug Administration (FDA) to treat chronic pain without a prescription. Users of this device will also have the option of using their smartphone to automatically track and personalise their pain therapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNeuroMetrix president Shai Gozani said: "We are excited to be on the cusp of entering the $4bn US over-the-counter pain relief market.
"We believe that as advanced wearable therapeutic technology, Quell represents a new pain relief category that will be attractive to consumers looking for non-pharmacological pain control options."
The company expects to make the device commercially available for customers in the second quarter of 2015.
NeuroMetrix develops wearable medical technology and point-of-care tests for patients and physicians to better manage chronic pain, nerve diseases and sleep disorders.
Image: Quell, wearable pain relief device. Photo: courtesy of Business Wire / NeuroMetrix.
